HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

JTE-952

a CSF1R tyrosine kinase inhibitor

Also Known As:

(2S)-3-((2-((3-(4-(4-cyclopropylbenzyloxy)-3-methoxyphenyl)azetidine-1-yl)carbonyl)pyridin-4-yl)methoxy)propane-1,2-diol

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azetines
    - Azetidines: 6
      - JTE-952: 4

Experts

1.	Ikegashira, Kazutaka: 3 articles (01/2020 - 01/2019)
2.	Inagaki, Koji: 3 articles (01/2020 - 01/2019)
3.	Miyagawa, Naoki: 3 articles (01/2020 - 01/2019)
4.	Hata, Takahiro: 2 articles (01/2020 - 01/2020)
5.	Kakefuda, Reina: 2 articles (01/2020 - 01/2020)
6.	Kitagawa, Yoshihiro: 2 articles (01/2020 - 01/2020)
7.	Matsuo, Yushi: 2 articles (01/2020 - 01/2020)
8.	Matsushita, Mutsuyoshi: 2 articles (01/2020 - 01/2020)
9.	Uesato, Naofumi: 2 articles (01/2020 - 01/2020)
10.	Yamaguchi, Takayuki: 2 articles (01/2020 - 01/2020)

Related Diseases

1.	Arthritis (Polyarthritis) 01/01/2019 - "JTE-952 was also effective against a mouse collagen-induced model of arthritis (mouse CIA-model). " 01/01/2020 - "JTE-952 significantly suppressed increases in the bone destruction score, the number of tartrate-resistant-acid-phosphatase-positive cells, and the severity of arthritis in the model mice. " 01/01/2023 - "In the present study, we investigated the therapeutic effect of JTE-952 on methotrexate (MTX)-refractory joint destruction in a clinically established adjuvant-induced arthritis rat model. " 01/01/2020 - "JTE-952 (≥3 mg/kg given orally) also significantly attenuated the CSF1-induced priming of lipopolysaccharide-induced tumor necrosis factor-alpha production in mice and arthritis severity in a mouse model of collagen-induced arthritis. "
2.	Rheumatoid Arthritis 01/01/2020 - "JTE-952 is a potentially clinically useful agent for various human inflammatory diseases, including rheumatoid arthritis." 01/01/2023 - "Therapeutic Effect of Colony Stimulating Factor 1 Receptor Kinase Inhibitor, JTE-952, on Methotrexate-Refractory Pathology in a Rat Model of Rheumatoid Arthritis."
3.	Experimental Arthritis 01/01/2020 - "In summary, JTE-952 potently inhibited human osteoclast formation in vitro and suppressed bone destruction in an experimental arthritis model, especially when combined with methotrexate. " 01/01/2020 - "Here, we investigated the effect of JTE-952, a novel CSF1R tyrosine kinase inhibitor, on osteoclast formation in vitro and on bone destruction in a mouse model of collagen-induced arthritis. " 01/01/2020 - "JTE-952 Suppresses Bone Destruction in Collagen-Induced Arthritis in Mice by Inhibiting Colony Stimulating Factor 1 Receptor." 01/01/2020 - "JTE-952 (≥3 mg/kg given orally) also significantly attenuated the CSF1-induced priming of lipopolysaccharide-induced tumor necrosis factor-alpha production in mice and arthritis severity in a mouse model of collagen-induced arthritis. "
4.	Pain (Aches) 01/01/2023 - "These results suggest that JTE-952 is expected to prevent the progression of the structural destruction of joints and its associated effects on joint motion and pain by inhibiting CSF1/CSF1R signaling in RA pathology, which is resistant to conventional disease-modifying anti-rheumatic drugs such as MTX."
5.	Inflammation (Inflammations) 01/01/2020 - "These results indicate that JTE-952 should strongly inhibit bone destruction and joint inflammation in RA patients and effectively prevent the progression of the structural destruction of joints."

Related Drugs and Biologics

1.	Collagen
2.	Methotrexate (Mexate)
3.	Therapeutic Uses
4.	Macrophage Colony-Stimulating Factor
5.	Antirheumatic Agents (DMARD)
6.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
7.	Phosphotransferases (Kinase)
8.	Lipopolysaccharides
9.	Tyrosine Kinase Inhibitors
10.	Tartrate-Resistant Acid Phosphatase